The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study

Randomized Controlled Trial

. 2021 Feb;121(1):167-173.

doi: 10.1007/s13760-019-01101-x. Epub 2019 Feb 23.

Affiliations

PMID: 30798472
DOI: 10.1007/s13760-019-01101-x

Randomized Controlled Trial

Narges Karimi et al. Acta Neurol Belg. 2021 Feb.

Abstract

Migraine is a disabling disorder that affects the quality of life of patients. Different medications have been used in prevention of migraine headache. In this study, we evaluated the effectiveness of magnesium oxide in comparison with valproate sodium in preventing migraine headache attacks. This is a single-center, randomized, controlled, crossover trial which is double-blind, 24-week, 2-sequence, 2-period, 2-treatment. After patient randomization into two sequences, the intervention group received magnesium oxide 500 mg and the control group received valproate sodium 400 mg two tablets each day (every 12 h) for 8 weeks. The primary efficacy variable was reduction in the number of migraine attacks and number of days with moderate or severe headache and hours with headache (duration) per month in the final of 8 weeks in comparison with baseline. Seventy patients were randomized and seven dropped out, leaving 63 for analysis. In an intention-to-treat analysis, 31 patients were in group 1 (magnesium oxide-valproate) and 32 patients were in group 2 (valproate-magnesium oxide). The mean number of migraine attacks and days per month was 1.72 ± 1.18 and 2.09 ± 1.70, with a mean duration of 15.50 ± 21.80 h in magnesium group and 1.27 ± 1.27 and 2.22 ± 1.96, with a mean duration 13.38 ± 14.10 in valproate group. This study has shown that 500 mg magnesium oxide appears to be effective in migraine prophylaxis similar to valproate sodium without significant adverse effect.

Keywords: Clinical trial; Crossover; Magnesium oxide; Migraine headache; Valproate sodium.

PubMed Disclaimer

Cited by

Magnesium (Mg2+): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation.
Kumar A, Mehan S, Tiwari A, Khan Z, Gupta GD, Narula AS, Samant R. Kumar A, et al. Curr Pharm Des. 2024;30(39):3074-3107. doi: 10.2174/0113816128321466240816075041. Curr Pharm Des. 2024. PMID: 39253923 Review.
New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.
Simonetta I, Riolo R, Todaro F, Tuttolomondo A. Simonetta I, et al. Int J Mol Sci. 2022 Mar 11;23(6):3018. doi: 10.3390/ijms23063018. Int J Mol Sci. 2022. PMID: 35328439 Free PMC article. Review.
Magnesium as an Important Factor in the Pathogenesis and Treatment of Migraine-From Theory to Practice.
Domitrz I, Cegielska J. Domitrz I, et al. Nutrients. 2022 Mar 5;14(5):1089. doi: 10.3390/nu14051089. Nutrients. 2022. PMID: 35268064 Free PMC article. Review.
Magnesium for Pain Treatment in 2021? State of the Art.
Morel V, Pickering ME, Goubayon J, Djobo M, Macian N, Pickering G. Morel V, et al. Nutrients. 2021 Apr 21;13(5):1397. doi: 10.3390/nu13051397. Nutrients. 2021. PMID: 33919346 Free PMC article. Review.
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial.
Khani S, Hejazi SA, Yaghoubi M, Sharifipour E. Khani S, et al. J Headache Pain. 2021 Apr 7;22(1):21. doi: 10.1186/s10194-021-01234-6. J Headache Pain. 2021. PMID: 33827421 Free PMC article. Clinical Trial.

References

1. Martin VT, Behbehani MM (2001) Towards a rational understanding of migraine trigger factors. Med Clin N Am 85:911–941 - DOI
1. Lipton RB, Liberman JN, Kolodner KB, igal ME, Dowson A, Stewart WF (2003) Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 23:441–450 - DOI
1. Stewart WF, Shechter A, Rasmussen BK (1994) Migraine prevalence. A review of population-based studies. Neurology 44 (6 Suppl 4):S17–S23 - PubMed
1. Shahbeigi S, Fereshtehnejad SM, Mohammadi N et al (2013) Epidemiology of headaches in Tehran urban area: a population based cross-sectional study in district 8, year 2010. Neurol Sci 34:1157–1166 - DOI
1. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642–648 - DOI

The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study - PubMed (original) (raw)